...
首页> 外文期刊>癌と化学療法 >A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA
【24h】

A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA

机译:5'-DFUR联合MPA治疗对多发性骨转移有长期生存的晚期复发乳腺癌

获取原文
获取原文并翻译 | 示例

摘要

The patient was a 69-year-old woman who had undergone right standard radical mastectomy on August 8, 1991, and was treated with chemo- and hormonal therapy of ADM, UFT and TMA. Three years later she showed multiple bone metastases with elevation of CEA, and 5'-DFUR 1,200 mg/day and MPA 800 mg/day were administered. Two years later her CEA levels were decreased, 5'-DFUR was discontinued and MPA 1,200 mg/day only was continued. Two months later a side effect of MPA, her body weight gain, was observed, and the dosage of MPA was reduced from 1,200 mg/day to 800 mg/day. Then the side effect was resolved. Bone scintigraphy and MRI showed that bone metastatic lesions were reduced 6 years after 5'-DFUR and MPA therapy. It is suggested that this combination therapy may be useful for advanced recurrent breast cancer patients with multiple bone metastases.
机译:该患者是一名69岁的妇女,她于1991年8月8日接受了正确的标准根治性乳房切除术,并接受了ADM,UFT和TMA的化学和激素治疗。三年后,她表现出多处骨转移,并伴有CEA升高,并给予5'-DFUR 1,200 mg /天和MPA 800 mg /天。两年后,她的CEA水平降低,停止使用5'-DFUR,仅继续每天MPA 1200 mg。两个月后,观察到MPA的副作用,即体重增加,MPA的剂量从1200 mg /天减少到800 mg /天。然后副作用得以解决。骨闪烁显像和MRI显示5'-DFUR和MPA治疗后6年,骨转移病变减少。建议这种联合疗法对患有多发性骨转移的晚期复发性乳腺癌患者可能有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号